Cirrhosis is an important cause of morbidity and mortality in people with chronic liver
disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to …

Background & Aims Accurate estimates for the contemporary burden of chronic liver disease
(CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the …

The natural history of cirrhosis is characterised by an asymptomatic compensated phase
followed by a decompensated phase, marked by the development of overt clinical signs, the …

The harmful use of alcohol has been estimated to cause approximately 3.3 million deaths
every year, corresponding to nearly 6% of all deaths globally. Therefore, the effective …

Background and aims Acute-on-chronic liver failure (ACLF) is characterised by acute
decompensation of cirrhosis associated with organ failures. We systematically evaluated the …

The human gut microbiome has emerged as a major player in human health and disease.
The liver, as the first organ to encounter microbial products that cross the gut epithelial …

The pathophysiological background of decompensated cirrhosis is characterised by a
systemic proinflammatory and pro-oxidant milieu that plays a major role in the development …

The clinical course of cirrhosis is mostly determined by the progressive increase of portal
hypertension, hyperdynamic circulation, bacterial translocation and activation of systemic …

Alcohol-related liver disease (ALD), which includes a range of disorders of different severity
and is one of the most prevalent types of liver disease worldwide, has recently regained …

Background & Aims Sorafenib is the recommended treatment for patients with advanced
hepatocellular carcinoma (HCC). We aimed to compare the efficacy and safety of a …